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Olfactory neuroblastoma (ONB) is a rare malignant neoplasm arising from the olfactory 
neuroepithelium1,2. Its incidence is 0.4 patients per million per year, and it represents about 3% of 
malignant tumours of the nasal cavity and paranasal sinuses3,4. Basal cells of the olfactory 
neuroepithelium are presumably the progenitors of the ONB. The neoplasm usually arises in the 
olfactory vault of the nasal fossa and it is intimately related to the cribriform plate. Often, diagnosis 
is made late because early stage ONBs are usually asymptomatic. The incidence of cervical 
metastasis varies from 5 to 12% at the time of diagnosis, whereas distant metastases occur in 12 to 
25% of patients. To date, no universally accepted classification systems have been adopted; the 
Hyams’ grading system is usually used to histologically grade the tumors and the Kadish system is 
used to stage them5,6. 
Cytogenetic data on ONB are scarce; in one study by Guled et al. (2008) the authors analysed tumor 
samples from 13 patients by array comparative genomic hybridization (a-CGH). The authors 
observed a number of recurrent chromosome region gains and losses, which might also be 
related to the tumor stage. In particular, gains of 20q and 13q were suggested to be important in 
cancer progression7. Here we present data on 13 DNA samples from12 patients with ONB analyzed 
by a-CGH. The aim of our study was to better define the cytogenetic profile of ONB by a-CGH, 
and identify possible correlations with clinical and pathological features, evaluating the advantages 
and limits of the technique. 
The analyzed patients were treated at the Department of Otolaryngology of Varese and followed 
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with a careful follow-up. At the Department of Pathology tumor samples of the patients were 
reviewed with the use of  immunohistochemical techniques to confirm the diagnosis of ONB. At the 
Section of Biology and Medical Genetics, Department of Clinical and Experimental Medicine of 
Varese, the DNA analysis of tumors were carried out using a-CGH technique. 
 
2. OLFACTORY NEUROBLASTOMA 
Olfactory neuroblastoma (ONB) is an uncomm malignant neuroectodermal nasal tumour. ONBs are 
thought to arise from the specialized sensory neuroepithelial (neuroectodermal) olfactory cells that 
are normally found in the upper part of the nasal cavity, including the superior nasal concha, the 
upper part of septum, the roof of nose, and the cribriform plate of ethmoid8. 
 
2.1 Clinical features 
 
Those tumors usually present with unilateral nasal obstruction and epistaxis. Impairment or loss of 
the sense of smell is not common as a clinical symptom as might be expected, in part because 
olfaction is preserved on the contra lateral side in some tumors and in part because some patients 
fail to notice its gradual loss. Extension into the intracranial cavity rarely causes neurological 
symptoms as invasion of the frontal lobe only produces symptoms after massive involvement. 
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Figure 1: Endoscopic view of olfactory neuroblastoma 
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2.2 Imaging Studies 
The imaging features of olfactory neuroblastoma are non-specific. Nevertheless, this neoplasm 
should be suspected when a mass is detected in the superior nasal cavity, causing either remodeling 
or destruction of adjacent bony structures, and erosion of the cribriform plate or of the fovea 
ethmoidalis9. 
The stage at initial presentation is highly predictive of survival and accurate staging is essential. 
Appropriate evaluation includes both computed tomography (CT) and magnetic resonance 
imaging (MRI), to help define the likely extent of the disease both at the primary site and in the 
neck. However, thosee imaging modalities are complimentary and should be performed in all cases. 
Fine-cut spiral overlapping CT scan in all three dimensions is the radiological study of choice. 
Olfactory neuroblastoma does not have any specific radiological appearance but its site in the 
olfactory cleft makes it a likely diagnosis in its early stages. It is seen is a homogenous soft-tissue 
mass in the nasal vault, with uniform and moderate contrast enhancement and occasionally the 
adjacent bone can be hyperostotic. CT images are essential for correct staging and should be 
carefully examined for erosion of the lamina papryacea, cribriform plate, and fovea ethmoidalis. 
MRI enables a better estimate of tumor spread into surrounding soft tissue and areas in particular it 
can indicate whether the tumor has involved or traversed the dura and/or the orbit and can 
differentiate mucus from tumor10. 
. 
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Figure 2: MR - aspects of ONB 
a. Coronal MR T1 with contrast shows a mass with a low- to intermediate signal, epicenter within 
the right ethmoid and intracranial extension. b On sagittal plane post contrast MR demonstrates that 
the tumor extends into the anterior cranial fossa c. A post contrast coronal MR of a case without 
intracranial spread into the anterior cranial fossa 
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2.3 Staging system 
Different staging systems based on the extension of the lesion11 have been specifically proposed for 
olfactory neuroblastoma (Table 1 and 2). 
 
Table 1: Kadish staging system 
Kadish staging system (1976) 
Stage Features 
A  Tumor confined to the nasal cavity  
B  Tumor confined to the nasal cavity, involving one or  more paranasal sinuses  
C  Tumor extending beyond the nasal cavity and paranasal sinuses. Includes involving of the   
     orbit, skull base, intracranial cavity, cervical lymph nodes and distant metastatic sites  
 
Table 2: Dulguerov and Calcaterra staging system 
Dulguerov and Calcaterra staging system (1992) 
Stage Features 
T1  Tumor involving the nasal cavity and/or paranasal sinuses, sparing the most superior ethmoidal 
cells  
T2  Tumor involving the nasal cavity and/or paranasal sinuses, including the sphenoid, with 
extension to and erosion of the cribriform plate  
T3  Tumor extending into the orbit or protruding into the anterior cranial fossa  
T4  Tumor involving the brain  
 
 
Kadish and co-workers11 were the first to propose a staging classification, using three categories, 
Group A, B and C (Table1). A further system was proposed with the advent of advances in imaging 
(241), based on the TNM system (Table 2). Although a system of classification has been proposed, 
various attempts have been made to modify the Kadish system11,12. Other authors suggest that by 
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using the Kadish staging system and the Hyams grading system independently they can predict 
patients outcome with more accuracy13. Hyams grading system is based on histology and will be 
referred in the next section. 
 
2.4 Histology 
Olfactory neuroblastoma is an uncommon sinonasal tumour, and can often been confused with 
other neoplasms, e.g. sinonasal undifferentiated carcinoma, neuroendocrine carcinoma, melanoma, 
lymphoma, plasmacytoma, embryonal rhabdomyosarcoma, Ewing’s sarcoma, peripheral primitive 
neuroectodermal tumours, vascular tumours etc.. It was this frustrating feature that prompted Ogura 
and Schenek14 to describe olfactory neuroblastoma as the “great impostor”. The diagnosis of 
olfactory neuroblastoma can be problematic and consequently, histochemical, immunochemical and 
ultrastructural investigations are often needed to support the diagnosis15. Westra and colleagues 
from Johns Hopkins reviewed 37 cases of diagnosed olfactory neuroblastoma and excluded 8 
(21.6%) because they did not meet diagnostic inclusion criteria16. Hirose et al.15 from the Mayo 
Clinic Tissue Registry reviewed 30 cases of olfactory neuroblastoma and found that 4 (13.3%) were 
excluded because they lacked neural or neuroendocrine markers. Exhibiting only epithelial markers, 
they were considered examples of sinonasal undifferentiated carcinoma. 
It is reported that a diagnosis of olfactory neuroblastoma by light microscopy is not difficult when 
the tumor is well differentiated and consists of homogenous small cells with uniform round to oval 
nuclei, with rosette or pseudorosette formation, and eosinophilic fibrillary intercellular background 
material. Hyams et al.17 proposed a grading system for olfactory neuroblastoma, Grades I being 
well differentiated to IV undifferentiated, based on several tumour histological parameters: 
preservation of lobular architecture, mitotic index, nuclear polymorphism, fibrillary matrix, the 
presence of HW (Horner Wright) or FW (Flexner-Wintersteiner) rosettes, and the presence or 
absence of tumour necrosis.  
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Table 3: Hyams’ grading system 
Olfactory neuroblastoma grading (based on Hyams’ grading system)  
Microscopic features Grade I Grade II Grade III Grade IV 
Architecture Lobular Lobular ±Lobular ±Lobular 
NF matrix Prominent Present May be present Present 
Rosettes HR HR FW FW 
Mitoses Absent Present Prominent Marked 
Necrosis Absent Absent Present Prominent 
Glands May be present May be present May be present May be present 
Calcification Variable Variable Absent Absent 
 
NF neurofibrillary, HR Homer Wright pseudorosettes, FW Flexner-Wintersteiner rosettes 
 
When the tumor is undifferentiated with anaplastic hyperchromatic small cells that show many 
mitotic figures and scant cytoplasm, differentiating the tumor from other small-cell nasal neoplasms 
by light microscopy becomes difficult. To summarise, the pathologic distinction of poorly 
differentiated small cell neoplasms of the nasal cavity is difficult and can only be based on the 
results of antigen expression using a panel of antibodies by immunohistochemistry and if necessary 
confirmed by electron microscopy. There is still a lack of consensus relating to these prognostic 
histological features. Support for the prognostic value of Hyams and co-workers grading17 has been 
published18. Histopathological staging according to Hyams has also been advocated more recently 
in predicting survival and prognosis19. Hirose and colleagues found that a high degree of S-100 
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immunopositivity and a low (<10%) Ki-67 labelled index (a marker for proliferation) was 
associated with better survival. There are conflicting data on the prognostic role of p53 tumor 
suppressor gene mutations13 . 
 
 
Table 4: Immunohistochemical features of olfactory neuroblastoma 
positive negative 




neurofilament protein (NFP) 
 
Cytokeratin 
epithelial membrane antigen (EMA) 


















Mean age 40–45 years 55–60 years <30 years 50 years 





sinus > nasal 
cavity 
Superior/posterior nasal 








Mass lesion with 
bone erosion 
May invade skull base or 
orbit 







>60% die of disease 
Cranial nerve Sometimes Common Sometimes Uncommon 
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Pattern Lobular Sheets and nests Sheets, nests Ribbons, islands 















Common Minimal Moderate 
Mitotic figures Variable High Common High 
Necrosis Occasionally Prominent Frequent Prominent 
Vascular 
invasion 
Occasionally Prominent Rare Present 
Neurofibrillary 
stroma 
Common Absent Absent Absent 
Pseudorosettes Common Absent Present Present 
Keratin Focal, weak >90% Rare Positive 
CK 5/6 Negative Negative n/a n/a 
EMA Negative 50% n/a n/a 
NSE >90% 50% Positive Positive 
S-100 protein + (sustentacular) <15% Rare Positive 
Synaptophysin >90% (can be 
weak) 
<15% Positive Positive 
In situ EBER Absent Absent Absent Absent 
Neurosecretory 
granules (EM) 
Numerous Rare Absent Present 
EBER Epstein barr virus encoded RNA (EBV-encoded RNA) 
Modified From: Thompson 2009  
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2.5 Treatment and results 
 
The Primary Site 
A combination of surgery and radiotherapy is the most frequently used approach, and the one that 
achieved the highest cure rates20. Despite the lack of support for single-modality treatment 
regimes21, a substantial number of patients are treated by surgery or radiotherapy alone. The 
difference in survival between the combined treatments and radiotherapy alone is significant. The 5-
year disease-specific survival in the literature is reported between 52–90%1. Surgery alone was 
associated with lower survival combined with a combination of radiotherapy and chemotherapy, or 
triple modality treatment (surgery, radiotherapy and chemotherapy). Although the results were 15-
20% better, the differences from the best combination were not statistically significant, probably 
because of the limited number of patients2. These results were complied from the MEDLINE 
database from 1990–2000, without language tags. There were 26 treatment studies that formed the  
basis for the above tabulations and data extracted from these studies comprised the total number of 
patients, the staging system used, the patients’ distributions by stage and the histological grade and 
the treatment used. Outcome data consisted of recurrence free survival at 3 years and 5 years, 
overall survival at 5 and 10 years, and the results by stage, grade and treatment modality. In five 
studies, olfactory neuroblastoma were histo-pathologically graded according to Hyams et al., the 
mean 5 year survival was 56% in patients with grades I or II tumours and 25% in those with 
tumours of grade III or IV. This difference was significant (odds ration 6.18 {95% CI 1.30 – 29.3}). 
In 25 studies that used the Kadish classification, the mean 5 year survival for these three groups was 
Group A 72%, Group B 59% and Group C 47%, respectively. On average, 5% (SD 7) of patients 
presented with cervical lymph node metastases. In the studies of survival data according to N stage, 
only 29% of N+ patients were treated successfully, compared with 64% of N0, a significant 
difference (Odds ratio 5.1 {95% CI 1.6 – 17.0}). 
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Most institutions favour surgery as the first treatment modality, followed by radiotherapy22,23,24. 
Endocranial extension and a close relation to the ethmoid roof and cribriform plate have 
conventionally led to a combined transfacial and neurosurgical approach. Craniofacial resection 
allows for an en bloc resection of the tumour with better assessment of any intracranial extension 
and protection of the brain and optic nerve. The resection should include the entire cribriform plate 
and crista galli. It is said that the olfactory bulb and overlying dura should be removed with the 
specimen although there is no clear evidence to support the assertion that the whole of the bulb 
should be removed25. Open surgery has long been regarded as the gold standard, with results 
available for decades. A craniotomy is probably not justified for T1 tumours where there is clear 
radiological evidence of a normal cribriform plate and no involvement of the upper ethmoidal cells 
although this clinical picture is seldom seen. The evolution of surgical techniques has created 
another surgical option in the form of endoanasal endoscopic surgery. The use of endoscopic 
surgery for olfactory neuroblastoma followed by the use of the stereotactic radiosurgical gamma 
knife therapy has recently been used26. One report of 10 cases with a mean follow-up of 38 months 
used endoscopic resection alone without any recurrence although only 2 had Kadish stage C 27. In 
the last decade, numerous articles with small numbers have been published on the endoscopic 
resection of olfactory neuroblastoma. Devaiah et al. reviewed the literature with a meta-analysis and 
showed that an endoscopic approach gave a better survival rate28. The aim of this study was to 
compare results of open, endoscopic, endoscopic-assisted, and nonsurgical treatments since the first 
publication that mentioned an endoscopic removal in the literature. This analysis extracted 
sufficient data in 361 subjects and the statistically significant results for the full cohort are 
summarized in Table 6.  
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Table 6: Olfactory neuroblastoma: comparison of survival results (1992 – 2008) according to 







Endoscopic surgery produced overall better survival rates than open surgery with no significant 
difference between follow-up times in the endoscopic and open surgery groups (Table 7).  
 
Table 7: Median Follow-up Times (months) for olfactory neuroblastoma  
 
As the gold standard open procedure considerably predated endoscopic treatment, they also grouped 
the data according to the publication year. The endoscopic surgery group maintained better survival 
rates. This data shows evidence for the efficacy of endoscopic surgery in olfactory neuroblastoma. 
There are more cases of long-term follow-up in the open surgery group than the endoscopic 
treatment group and most of the open surgery tumors belonged to the Kadish C stage, whereas the 
endoscopic techniques were used more commonly for Kadish A and B tumors. This reflects how 
endoscopic surgery has mainly been used for less extensive lesions. This might not only be a 
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reflection of the size of the tumor but their pathology as more extensive lesions might be expected 
to be more invasive and less differentiated although this cannot be ascertained from the data 
available 28. The most recent publication on endoscopic endonasal resection for all Kadish groups 
has just been published by Folbe et al. 29. This is a retrospective, multicenter study with 23 patients 
operated endoscopically with postoperative radiotherapy in 16 patients. The mean follow-up was 
45.2 months with one recurrence. The authors conclude that endoscopic surgery is replacing 
craniofacial resection and that oncologic control is not sacrificed when good endoscopic resection 





Standard radiotherapeutic techniques include external megavoltage beam and a three-field 
technique; an anterior port is combined with wedge later fields to provide a homogeneous dose 
distribution. The doses range from 55 Gy to 65 Gy with the majority receiving above 60 Gy. 
Currently it is considered that radiotherapy should play a role in the management of olfactory 
neuroblastoma, particularly in patients who have had incomplete surgical resection or who present 
with residual disease . In a small retrospective series, a comparison was made between conventional 
radiotherapy and stereotactically guided conformal radiotherapy (SCRT). It was concluded that 





Olfactory neuroblastoma is regarded as a chemosensitive tumour based on multiple reported 
responses to treatment31. Neoadjuvant therapy is seldom curative on its own and it may be of no 
benefit in some patients. Individuals who respond to preoperative chemotherapy have a greater 
chance of long term disease-free surviva. It has been proposed that Hyams’ grading is an important 
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predictor of response to chemotherapy31, and it has been suggested that cisplatinbased 
chemotherapy is helpful in advanced, high-grade olfactory neuroblastoma and should be considered 
the choice in the systemic treatment of these patients. 
Neoadjuvant chemotherapy has been advocated for patients with advanced disease at the University 
of Virginia over a 20 year period32. In thirty four consecutive patients, two thirds showed a 
significant reduction of tumour burden with adjuvant therapy and patients that showed a response to 
neoadjuvant therapy demonstrated a significantly larger disease- free mortality rate. Preoperative 
chemotherapy consisted of cyclophosphamide (650 mg/m2) and vincristine (1.5 mg/m2; maximal 
dose, 2 mg) there were administered every 3 weeks for 6 cycles. Adriamycin was used in 
combination with cyclosphosphamide in two patients. Most patients also received a total dose of 50 







3. ARRAY COMPARATIVE GENOMIC HYBRIDIZATION 
 
3.1 a-CGH definition and technique 
 
Chromosomal CGH was first introduced by Kallioniemi et al.33 and has rerevolutionized 
cytogenetic studies over past decades. The precept of chromosomal CGH is competitive 
hybridization of equal amounts of test and normal genomic DNA onto metaphase chromosome 
spreads. Subsequent quantitative analysis delineates chromosomal aberration (gain or loss). A major 
limitation of this method, however, is its restricted resolution of 10-20 Mb34. 
This problem was overcome by the introduction of array CGH, in which a collection of mapped and 
annotated genomic clones replace metaphase chromosomes35, allowing for higher resolution and 
identification of clones harbouring potential oncogenes and tumor suppressor genes.  
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The application of microarray-based comparative genomic hybridization (array CGH) to diagnostics 
is transforming the field of clinical cytogenetics. Array CGH compares DNA content from two 
differentially labeled genomes. The two genomes, a test (or patient) and a reference (or control), are 
cohybridized onto a solid support (usually a glass microscope slide) on which cloned or synthesized 
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Figure 3. Schematic representation of CGH microarray technology. Whole genomic DNA from a control or reference (left) and genomic DNA 
from a test or patient (right) are differentially labeled with two different fluorophores. The two genomic DNA samples are competitively cohybridized 
with large- insert clone DNA targets that have been robotically printed onto the microarray (middle). Computer imaging programs assess the relative 
fluorescence levels of each DNA for each target on the array (lower left). The ratio between control and test DNA for each clone can be linearly 




Arrays have been built with a variety of DNA substrates that may include oligonucleotides, cDNAs, 
or bacterial artificial chromosomes (BACs). The resolution of the array is limited only by the size of 
the cloned DNA targets and the natural distance between these sequences located on the 
chromosome. The primary advantage of array CGH over fluorescence in situ hybridization (FISH) 
is the array’s ability to detect DNA copy changes simultaneously at multiple loci in a genome. 
These changes may include deletions, duplications, or amplifications at any locus as long as that 
region is represented on the array. Thus, array CGH is a coordinated and concurrent FISH 
experiment over hundreds or thousands of loci. In contrast, FISH on metaphase or interphase cells 
is limited by the number of probes that can be used simultaneously. In addition, FISH requires 
clinical suspicion that a specific locus in the genome has undergone copy-number change. This 
knowledge dictates the choice of probe for the FISH analysis and the examination of either 
interphase nuclei or metaphase chromosomes. Finally, FISH analysis on metaphase chromosomes 
detects only microdeletions, since FISH even on interphase nuclei may fail to identify duplications. 
 
 
3.2 Principles and research applications of Array CGH  
 
Array CGH is based on the same principle as traditional metaphase CGH. In both techniques, whole 
genomic DNA from a control (or reference) and genomic DNA from a test (or patient) are 
differentially labeled with two different fluorophores and used as probes that are cohybridized 
competitively onto nucleic acid targets. In traditional metaphase CGH, the target is a reference 
metaphase spread. In array CGH, these targets can be oligonucleotides, cDNAs, or genomic 
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fragments that are cloned in a variety of vectors such as plasmids, cosmids, BACs, or P1 artificial 
chromosomes. 
The resolution of array CGH is defined by two main factors: 1) the size of the nucleic acid targets 
and 2) the density of coverage over the genome; the smaller the size of the nucleic acid targets and 
the more contiguous the targets on the native chromosome, the higher the resolution of the array. 
The use of array CGH in research has accelerated the pace of gene discovery in human genetics, 
deepened the understanding of genomic changes in cancer, and furthered the study of fundamental 
concepts related to chromosome conformation, DNA methylation, histone acetylation, gene 
silencing, replication timing, and many other basic mechanisms pertaining to DNA structure and 
function36,37. The high resolution afforded by array CGH has been used to define candidate regions 
for putative genes responsible or human genetic diseases. For example, Vissers et al38 hybridized 
cell lines from two individuals with CHARGE syndrome onto a genome-wide array with a 1-Mb 
resolution. The authors used a 918-BAC tiling resolution array to narrow a candidate region for 
CHARGE syndrome on 8q12 based on data from two individuals, one with a 5-Mb deletion and 
another with a more complex rearrangement comprising two deletions that overlapped that of the 
first deletion subject. These results allowed the authors to focus on only nine genes in the region 
and detect heterozygous mutations in the gene CHD7, which was eventually shown to be the gene 
for CHARGE syndrome. The high resolution of that array was crucial in refining the critical region 
for this diseaseand in reducing the number of candidate genes to be investigated further. Array CGH 
has proven useful in providing DNA copy number “signatures” or profiles for various cancers. 
Many cancers are associated with multiple gains and losses of chromosomes and chromosomal 
segments. Given the difficulties associated with culturing and obtaining quality metaphases from 
most solid tumors, approaches that directly examine the DNA content and link any dosage changes 
to chromosome abnormalities are highly desired. 
The hope of these studies is that certain signatures become prognostic markers and can guide 
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3.3 a-CGH and olfactory neuroblastoma 
 
The cytogenic data on ONB from the literature are rather sparse: therefore we decided to compare 
our results with those Guled et al. (2008), who reported a-CGH results obtained on 13 patients, and 
reviewed all previous reports in the literature. Early suggestions that ONB is a form of peripheral 
neuroectodermal tumour have been subsequently disproven in multiple studies. In these studies, 
reverse transcriptase-PCR or FISH failed to find the EWS-FLI1 fusion transcript or EWS 
rearrangement in any candidate ONB. These findings explain the demonstrated absence of CD99 
immunohistochemical staining in ONB39.   
In 1997 Szymas et al describe genomic imbalances of olfactory neuroblastoma in a 46-year-old 
woman by using the molecular cytogenetic technique - comparative genomic hybridization (CGH) 
for the first time in order to define the spectrum of genetic abnormalities in the tumor.  
The CGH analysis showed multiple changes including DNA overrepresentations of chromosomes 4, 
8, 11 and 14, partial DNA gains of the long arms of chromosomes 1 and 17, deletions of the entire 
chromosomes 16, 18, 19 and X, and partial losses of chromosomes 5q and 17p. This study 
represents an early utilisation of the CGH technique in olfactory neuroblastoma and demonstrates 
that the tumour carries complex chromosomal aberrations40. 
In the study of Riazimand the genomic imbalances of three ONB were analyzed by CGH to 
evaluate a recurrent pattern of imbalances and its relation to the pPNET family. The CGH analysis 
revealed multiple recurrent aberrations including DNA overrepresentations of chromosomal 
material of the entire chromosome 19, partial gains of the long arms of chromosomes 8, 15, and 22, 
and deletions of the entire long arm of chromosome 4. Beside these common aberrations, several 
single gains and losses occurred, that is, gains on 6p, 10q, 1p, 9q, and 13q. Their findings confirmed 
the former observation of amplified genetic material on chromosome 8 and found several new, 
currently not described recurrent genetic aberrations distinct from those described for pPNET and 
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give evidence that ONB is not part of the pPNET family. They suggest that the combined gain of 
genetic material on 15q, 22q, and chromosome 8 might be indicative for ONB 41. 
 
Bockmuhl et al. reported on findings in ONB by conventional comparative genomic hybridization 
including frequent deletions of 1p, 3p/q, 9p, and 10p/q, and amplifications of 17q, 17p13, 20p, and 
22q. They also noted a deletion on chromosome 11 and gain on chromosome 1p, which were 
apparently associated with metastasis and a worse prognosis. The study included 12 patients42. 
Table 8: Most common alterations in ONB found in Bockmuhl’s paper  
 
 
Another study by Holland et al. has similarly shown complex cytogenetic changes in ONB. They 
performed comprehensive cytogenetic analyses of an ONB, Hyam's grade III-IV, using trypsin-
Giemsa staining (GTG banding), multicolor fluorescence in situ hybridization (M-FISH), and locus-
specific FISH complemented by molecular karyotyping using high-density single nucleotide 
polymorphism arrays. Therefore, their study supported the usefulness of applying complementary 
methods for cytogenetic analysis43  (Table 9). 
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Table 9: cytogenetic features showed in Holland’s paper 
 
Guled et al. performed an oligonucleotide-based aCGH analysis on 13 olfactory neuroblastoma 
samples, which was the first time that array-based CGH was applied to study the copy number 
changes in this neoplasm. Several copy number changes reported in previous studies were observed 
in their study, with identical, overlapping, or slightly different minimal common regions of 
alteration. Gains at the distal parts of 1p, 4, 9p, 13q, 15q, 22q, and 21q, and deletions at 4p and X, 
were reported in at least one study. Gains at 7q11 and 20q and deletions at 2q, 5q, 6p, 6q, and 18q 
were detected in two studies. 
Overall, olfactory neuroblastomas have highly complex copy number changes that occur over the 
entire genome. All samples analyzed showed genomic imbalances with slightly more gains than 
losses. a-CGH revealed more copy number changes than previous studies that used conventional 
CGH. Furthermore, their results showed novel aberrations, which were not described in previous 
reports. In accordance with at least two previous studies, they found gains at 7q11.2 and 20q13, and 
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losses at 2q31–q37, 5q, 6p, 6q, and 18q. In addition to these previously reported alterations, they 
identified novel gains in their  samples at 5q34–q35, 6p12.3, 10p12.31, 12q23.1–q24.31, and all of 
chromosome X. Losses at 15q11.2–q24.1, 15q13.1, 19q12–q13, 22q11.1–q11.21, 22q11.23, and 
22q12.1 have not been described previously. 
They identified a 770 kb region of chromosomal gain at 7q11.2. This region has been implicated in 
other cancers, and is overexpressed in prostate carcinomas, adenoid cystic carcinomas, head and 
neck squamous cell carcinomas, and pancreatic endocrine tumors.  
A 6 Mb region of gain at 20q13.32–q13.33 was also identified. DNA copy number increases at 
chromosome 20q13 have been observed frequently in a variety of cancers, including breast, ovarian, 
and squamous cell carcinomas, suggesting that the region harbors one or more oncogenes.  
Losses occurring at chromosome 2q have been described for various carcinomas, including head 
and neck squamous cell carcinoma, breast carcinoma, lung carcinoma, neuroblastoma, cervical 
cancer and prostate adenocarcinoma. Studies using different approaches have increasingly shown 
that the most affected region is 2q32–q37. This region also seems to be implicated in the 
development of ONB, as it has been reported in three cytogenetic studies including their 
investigation. 
Another area of loss identified in their study, and also reported by Bockmuhl et al.  and Holland et 
al., is located at 6q21–22. This region is frequently deleted in a variety of neoplasms, including 
pancreatic endocrine tumours, prostate carcinoma, breast carcinoma, and central nervous system 
lymphomas. 
Their study also identified two small gains at 9p13.3 (782 kb) and 13q34 (363 kb) that were 
previously reported by Holland et al. The 9p13.3 locus has been shown to be gained in prostate 
cancer cell lines in two recent studies using aCGH. Gains at 13q34 have also been described 
previously in different cancers, including breast cancer, hepatocellular carcinoma, esophageal 
squamous cell carcinoma, and lung adenocarcinoma. 
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As for most tumors, stage is the most important parameter associated with survival in olfactory 
neuroblastoma. Their results clearly indicate that alterations in 20q and 13q are important in the 
progression of olfactory neuroblastoma. Gain of 20q has been widely associated with progression of 
several tumours, including breast carcinoma, cervical carcinoma, and pancreatic carcinoma. Both 
losses and gains of chromosome 13q have been noted in many recent studies of various tumours, 
suggesting the existence of novel oncogenes or tumour suppressor genes or both in this region. 
Furthermore, this region has been reported to contain microRNAs that could function as tumour 
suppressor genes or oncogenes7. 
Gains of both 13q and 20q are seen in colorectal carcinomas and their progression.  
A number of genes located at these sites have been suggested to be important, but none of these 
changes has been sufficiently recurrent overall to be helpful in diagnosis, prognosis, or treatment 
and there have been no single gene mutations found in ONB to unify the entity or aid in its 
diagnosis. These various studies have, however, identified candidate regions for further study44 . 
 
Fig. 4 Frequency profile of copy number aberrations in 13 olfactory neuroblastoma samples. CGH Explorer software and Piecewise  
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Constant Fit algorithm were used to determine copy number aberrations in olfactory neuroblastoma samples. The chromosomal 
alterations are shown in each probe position as incidence bar. Gains of genomic material are indicated in gray on the upper s ide of the 
middle line (at 0). Losses are indicated in black on the bottom side of the middle line. Genomic positions o f the aCGH probes are marked 
on the x axis.  
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4. MATHERIALS AND METHODS                              
 4.1 Patients  
In our study we analyzed DNA from 13 patients affected by ONB and treated at the Ospedale di 
Circolo di Varese, University of Insubria.  
The patients were diagnosed and staged using the Kadish system (Kadish et al., 1976), and Hyams’ 
criteria (Hyams et al., 1988) were used for histological grading of the tumors. In each case, the 
diagnosis of ONB was established with hematoxylin/ eosin stained tissue sections and based on 
microscopic findings. In total, we a-CGH assayed 14 samples: ten primary tumors, two relapsed 
tumors, and two samples were from the same patient at onset and at relapse. DNA was extracted 
from paraffin-embedded tissues in nine cases, choosing the area in which the tumor cells 
represented > 50% of the total cell population, while four DNA samples were derived from fresh 
tumor material (Table 10). 
 
 
 Table 10  Clinical data on olfactory neuroblastomas 
 










F-up Status DNA 







ERTC  DNA 
(FFPE) 
2 62 F 
C 
III P 
ERTC 113 NED DNA 
(FFPE) 
3 64 M 
C 
II R 
CER 126 AWD DNA 
(FRESH) 
4 41 M 
B 
II R 
CER 166 NED DNA 
(FFPE) 
5 69 M 
C 
II P 
ERTC 139 NED DNA 
(FFPE) 
6 33 F 
B 
II P 
ERTC 66 NED DNA 
(FFPE) 
7 77 F 
B 
I P 
ERTC 82 NED DNA 
(FFPE) 
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8 33 F 
B 
II P 
ERTC 100 NED DNA 
(FRESH) 
9 44 M 
C 
II P 
ERTC 86 NED DNA 
(FFPE) 
10 48 M 
B 
II P 
ERTC 81 NED DNA 
(FFPE) 
11 80 F 
B 
III P 
ERTC 50 NED DNA 
(FFPE)  
12 62 F 
C 
II P 
ERTC 27 NED DNA 
(FRESH) 
13 53 F 
C 
II P 





ERTC: endoscopic resection with transnasal craniectomy; CER: cranioendoscopic resection 
Follow-up in months 
NED: no evidence of disease; AWD: alive with disease 
FFPE: fixed and paraffin-embedded material; FRESH: tumor tissue obtained during surgery 
 
Table 10 summarizes the surgical treatment, the disease status and the follow-up time for each 
patient, together with some clinicopathological data. Follow-up of the patients ranged from 14 to 
179 months, with a mean of 60 months. Patient age ranged from 33 to 80 years, and all patients are 
alive. Two patients are alive with disease (leptomeningeal metastases). All patients received a 
radical surgical treatment and underwent postoperative radiotherapy except patient no.1 that refused 
it. 
 
4.2 Hystological method  
 
All tissues were fixed in buffered formalin (formaldehyde 4% w/v and acetate buffer 0.05M) and 
routinely processed to paraffin wax. Five μm-thick sections were stained with hematoxylin-eosin 
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(H&E) for morphological evaluation. For immunohistochemistry, three µm-thick sections were 
mounted on poly-L-lysine coated slides, deparaffinized and hydrated through graded alcohols to 
water. After endogenous peroxidase activity inhibition, performed by dipping sections in 3% 
hydrogen peroxide for 10 minutes, sections were treated in citrate buffer pH 6 in a microwave oven 
at 750W for 10 minutes for antigen retrieval. Successively, sections were incubated with primary 
antibodies at 4°C for 18–20 hours, followed by the avidin-biotin complex (ABC) procedure. 
Immunoreactions were developed using 0.03% 3,3’diaminobenzidine tetrahydrochloride and then 
sections were counterstained with Harris’ hematoxylin. Specificity controls consisted of substitution 
of the primary antibody with non immune serum of the same species at the same dilution and use of 





Figure 5: histological features of ONB 
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4.3 Technique of a-CGH 
At the Department of Clinical and Experimental Medicine, University of Insubria of Varese, was 
performed the genetic analysis for identification and characterization of DNA imbalances in 
olfactory neuroblastomas by oligonucleotide array-based CGH. 
DNA was obtained from nine formalin-fixed and paraffin-embedded tissue samples using 
representative 8-mm sections of the tumor samples. In detail, three sections from each specimen 
were treated twice with xylene, and then washed twice with ethanol. DNA was extracted using the 
QIAampVR DNA FFPE Tissue kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
protocol. Neoplastic areas were manually microdissected for DNA extraction and contained at least 
50% tumor cells, to minimize contamination by normal cells45. For fresh specimens the average 
percentage of tumor cells was first evaluated during surgery by frozen section examination.  
Sections of these specimens with >50% tumor cells were then mechanically reduced into tiny 
pieces, and DNA was then extracted with the Quiagen Blood and Tissue kit (QIAGEN GmbH, 
Hilden, Germany). Chromosome imbalances were defined by a-CGH with the whole-genome 244K 
platform (Agilent Technologies, Santa Clara, CA) according to the manufacturer’s instructions for 
samples 1 and 5, while in samples nos. 2-4, 6-13 a 4x180K platform was used. The Agilent 
reference protocol used was: “Agilent Oligonucleotide Array-Based CGH for Genomic DNA 
Analysis Enzymatic Labelling for Blood, Cells or Tissues (version 7.1).” Slide images were 
acquired with Agilent’s microarray scanner G2565CA and features were extracted by Agilent’s 
Feature Extraction 10.7.3.1 software, and the a-CGH profiles were extrapolated with the Agilent’s 
Genomic Workbench software 6.5.0.18 using the following parameters/algorithms: ADM2 
(Threshold 6.0), Fuzzy zero (on), Centralization (on), default feature filter (on). An aberration filter 
algorithm (parameters: minimum number of probes per region =15, minimum absolute average log 
ratio values per region =0.3, maximum number of aberrant region =100, percent of penetrance per 
features =0) was applied to filter-out all the aberrations below 30% of mosaic level 46. 
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The Agilent Oligonucleotide Array-Based CGH for Genomic DNA Analysis (for FFPE Samples) 
user guide (Version 1.0, P/N G4410-90020) is available at www.agilent.com/chem/dnamanuals- 
protocols for a detailed description of the protocol used.  
 
 




Purification of genomic DNA from formalin-fixed, paraffin-embedded tissues (FFPE) 
The procedure to isolate genomic DNA (gDNA) from formalin-fixed paraffin-embedded (FFPE) 
samples is based on the method described by van Beers et al. (van Beers et al 2006) using the 
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Qiagen DNeasy Blood & Tissue Kit (p/n 69504). 
The protocol used is from QIAGEN Technical Service Departments (www.qiagen.com) 
Procedure: 
Step 1. Paraffin Removal 
1. Equilibrate a heat block or water bath to 90 °C and a thermomixer to 37 °C. 
2 .Put up to 5 20-micron FFPE sections into a 1.5 mL nuclease-free microfuge tube. 
3. Prepare 10% Tween 20, by adding 100 μL Tween 20 to 900 μL of nuclease-free water. The 
solution can be prepared in advance and stored up to 6 months at room temperature. 
4. Add 480 μL PBS and 20 μL 10% Tween 20 to the FFPE sections in the 1.5 mL nuclease-free 
microfuge tube. 
5. Transfer the sample tube to a circulating water bath or heat block at 90 °C. Incubate at 90 °C for 
10 minutes. 
6. Spin immediately for 15 minutes at 10,000 x g in a microcentrifuge. Put the sample tube on ice 
for 2 minutes. 
7. Remove the resulting wax disc with a pipette tip or tweezers. Remove and discard the 
supernatant without disturbing the pellet. 
8. Add 1 mL of 100% ethanol to the pellet and vortex briefly. Spin for 5 minutes at 10,000 x g in a 
microcentrifuge. 
9. Remove ethanol without disturbing the pellet and let the sample tube sit at room temperature with 
the lid open until residual ethanol has completely evaporated. 
10. Prepare a 1M NaSCN solution by adding 10 g of NaSCN to 123 mL of nuclease free water. The 
solution can be prepared in advance and stored up to 1 month at room temperature. 
11. Add 400 μL 1M NaSCN to the dry pellet and briefly mix on a vortex mixer.  
12. Transfer the sample tube to a thermomixer at 37 °C. Incubate overnight at 37 °C. Shake at 450 
rpm. 
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Step 2. Proteinase K Treatment  
1. Equilibrate a thermomixer to 55 °C. 
2. Transfer the sample tube to a microcentrifuge. Spin for 20 minutes at 10,000 x g.  
3. Remove and discard the supernatant without disturbing the pellet. 
4. Add 400 μL PBS to the pellet and vortex briefly. 
5. Spin again for 20 minutes at 10,000 x g in a microcentrifuge. 
6. Remove and discard the supernatant without disturbing the pellet. 
7. Add 360 μL of Qiagen buffer ATL (supplied with Qiagen DNeasy Blood & Tissue Kit).  
8. Add 40 μL proteinase K (supplied), mix well on a vortex mixer, and incubate overnight in a 
thermomixer at 55 °C shaking at 450 rpm. 
9. Transfer the sample tube to a microcentrifuge. Spin for 30 seconds at 6,000 x g to drive the 
contents off the walls and lid. 
10. Add 40 μL proteinase K, mix well on a vortex mixer, and incubate in a thermomixer for 
approximately 6 to 8 hours at 55 °C shaking at 450 rpm. 
11. At the end of the day, transfer the sample tube to a microcentrifuge and spin for 30 seconds at 
6,000 x g to drive the contents off the walls and lid. 
12. Add 40 μL proteinase K, mix well on a vortex mixer and incubate overnight in a thermomixer at 
55 °C shaking at 450 rpm. 
 
Step 3. gDNA Extraction  
1. Equilibrate a heat block or water bath to 56 °C. 
2. Let samples cool to room temperature and spin in a microcentrifuge for 30 seconds at 6,000 x g 
to drive the contents off the walls and lid. 
3. Add 8 μL of RNase A (100 mg/mL), mix on a vortex mixer, and incubate for 2 minutes at room 
temperature. Transfer the sample tube to a microcentrifuge and spin for 30 seconds at 6,000 x g to 
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drive the contents off the walls and lid. 
4. Add 400 μL Buffer AL (supplied), mix thoroughly on a vortex mixer, and incubate in a 
circulating water bath or heat block at 56 °C for 10 minutes. Transfer the sample tube to a 
microcentrifuge and spin for 30 seconds at 6,000 x g to drive the contents off the walls and lid.  
5. Add 440 μL 100% ethanol, and mix thoroughly on a vortex mixer. Transfer the sample tube to a 
microcentrifuge and spin for 30 seconds at 6,000 x g to drive the contents off the walls and lid.  
6. Put two DNeasy Mini spin columns in two clean 2 mL collection tubes (supplied). Split the entire 
sample mixture onto two DNeasy Mini spin columns (i.e. 660 μL each). 
7. Spin in a microcentrifuge for 1 minute at 6,000 x g. Discard the flow-through and collection tube. 
Put the DNeasy Mini spin columns in fresh 2 mL collection tubes (supplied). 
8. Before using for the first time, prepare Buffer AW1 by adding 100% ethanol to the Buffer AW1 
bottle (supplied; see bottle label for volume). Mark the appropriate check box to indicate that 
ethanol was added to the bottle. 
9. Add 500 μL Buffer AW1 onto each spin column, and spin in a centrifuge for 1 minute at 6,000 x 
g. Discard the flow-through and collection tube. Put the DNeasy Mini spin columns in fresh 2 mL 
collection tubes (supplied). 
10. Prepare a fresh 80% ethanol solution by adding 40 mL 100% ethanol to 10 mL nuclease-free 
water. 
11. Add 500 μL 80% ethanol onto each column, and spin in a microcentrifuge for 3 minutes at 
20,000 x g to dry the column membrane. Discard the flow-through and collection tube. 
12. Put the DNeasy Mini spin column in a clean 1.5 mL microcentrifuge tube, and add 50 μL of 
nuclease free water directly to the center of each spin column. 
13. Let stand at room temperature for 1 minute, and then spin in a microcentrifuge for 1 minute at 
6,000 x g to elute the DNA. 
14. Combine the purified DNA from the same sample in one microcentrifuge tube for a final total 
 Luca Volpi - Identification and characterization of cytogenetic profile in olfactory neuroblastoma 
by array comparative genomic hybridization  - Tesi di dottorato in Scienze biomediche – 
Curriculum di Oncologia molecolare XXIX ciclo  - Università degli studi di Sassari 
 
39 
volume of 100 μL. 
 
DNA Labeling 
Step 1. Preparation of gDNA Before Labeling 
1. Estimate the average molecular weight for each gDNA sample based on the agarose gel analysis  
2. If the gDNA concentration isless than required, concentrate the sample using a concentrator  
before you continue to the heat fragmentation. 
3. Put the appropriate amount of gDNA and nuclease-free water in a 0.2 mL nuclease-free PCR tube 
or plate to achieve the volumes 
 
Step 2. Heat Fragmentation  
1. Incubate the gDNA at 95 °C in a thermocycler with heated lid for the time to fragment the 
gDNA.  
2. Transfer the sample tubes to ice and incubate on ice for 3 minutes. You can also hold at 4 °C for 
3 minutes in a thermocycler. 
3. Spin in a microcentrifuge for 30 seconds at 6,000 × g to drive the contents off the walls and lid.  
 
Step 3. ULS Labeling 
1.Prepare one Cy3 and one Cy5 Labeling Master Mix by mixing the components, based on your 
microarray format and sample type. Avoid pipetting volumes less than 2 μL to ensure accuracy. 
2.Add the appropriate amount of Labeling Master Mix to each PCR tube containing the gDNA to 
make a total volume. Mix well by gently pipetting up and down. 
3.Transfer PCR tubes or plates to a thermocycler with heated lid and incubate at 85 °C for 30 
minutes. 
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4.Transfer the samples to ice and incubate on ice for 3 minutes. You can also hold at 4 °C for 3 
minutes in a thermocycler. 
5.Spin in a microcentrifuge for 1 minute at 6,000 × g to drive the contents off the walls and lid.  
Labeled gDNA can be stored on ice until dye removal using the Agilent KREApure columns or the 
Agilent Genomic DNA 96-well Purification Module. 
 
Step 4. Removal of non-reacted ULS-Cy 
Non-reacted ULS-Cy3 or ULS-Cy5 can interfere with the subsequent microarray experiment and 
increase background noise if they are not efficiently removed prior to hybridization. The Agilent 
KREApure columns or Genomic DNA 96-well Purification Module effectively removes non-
reacted ULS dye. 
 
Preparation of Labeled Genomic DNA for Hybridization 
1. Prepare the 100X Blocking Agent: 
a. Add 135 μL of nuclease-free water to the vial containing lyophilized 10X CGH Blocking 
Agent (supplied with Agilent Oligo aCGH Hybridization Kit).  
b. Mix briefly on a vortex mixer and leave at room temperature for 60 minutes to reconstitute 
sample before use or storage. 
c. Cross out “10X” on the label on the blocking agent vial and write “100X”. You are actually 
making a 100X Blocking Agent, so you need to relabel the 
vial of lyophilized blocking agent as such. 
The 100X Blocking Agent can be prepared in advance and stored at -20 °C. 
2. Equilibrate water baths or heat blocks to 95 °C and 37 °C or use a thermocycler. 
3. Prepare the Hybridization Master Mix by mixing the components in the table below according to 
the microarray format. 
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4. Add the appropriate volume of the Hybridization Master Mix to the 1.5 mL microfuge tube, tall 
chimney plate well or PCR plate well containing the labeled gDNA to make the total volume  
5. Mix the sample by pipetting up and down, and then quickly spin in a centrifuge to drive the 
contents off the walls and lid. 
6. Incubate the samples:  
a Transfer sample tubes to a circulating water bath or heat block at 95 °C. 
Incubate at 95 °C for 3 minutes. 
b Immediately transfer sample tubes to a circulating water bath or heat block at 37 °C. Incubate 
at 37 °C for 30 minutes or Transfer sample tubes to a thermocycler. Program the thermocycler  
7. Remove sample tubes from the water bath, heat block or thermocycler. Quickly spin in a 
centrifuge to drive the contents off the walls and lid. 
8. Bring the Agilent-CGHblock (supplied with the ULS Labeling Kit) to room temperature. 
Make sure that the Agilent-CGHblock is completely equilibrated to room temperature before you 
continue. 
9. Add the appropriate volume of Agilent-CGHBlock to each well or 1.5 mL microfuge tube 
containing the labeled gDNA and Hybridization Master Mix to make the final volume of 
hybridization sample mixture. 
Mix well by pipetting up and down. 
10. Quickly spin in a centrifuge to drive the contents off the walls and lid.  
 
Microarray Processing and Feature Extraction 
Step 1. Microarray Hybridization  
Step 2. Wash Preparation  
Step 3. Microarray Washing  
Step 4. Microarray Scanning using Agilent SureScan, C or B Scanner  
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Step 5. Data Extraction using Feature Extraction Software  
 
Microarray processing consists of hybridization, washing, and scanning. 
Feature Extraction is the process by which data is extracted from the scanned microarray and 
translated into log ratios, allowing researchers to measure DNA copy number changes in their 




Step 1. Microarray Hybridization 
Hybridization Assembly 
1. Load a clean gasket slide into the Agilent SureHyb chamber base with the gasket label facing up 
and aligned with the rectangular section of the chamber base. Ensure that the gasket slide is flush 
with the chamber base and is not ajar. 
2. Slowly dispense 490 μL (for 1x microarray), 245 μL (for 2x microarray), 100 μL (for 4x 
microarray) or 40 μL (for 8x microarray) of hybridization sample mixture onto the gasket well in a 
“drag and dispense” manner. For multi-pack microarray formats (i.e. 2x, 4x or 8x microarray), load 
all gasket wells before you load the microarray slide. For multi-pack formats, refer to “Agilent 
Microarray Layout and Orientation” 
3. Put a microarray slide “active side” down onto the gasket slide, so the numeric barcode side  is 
facing up and the “Agilent”-labeled barcode is facing down. Assess that the sandwich-pair is 
properly aligned. 
4. Put the SureHyb chamber cover onto the sandwiched slides and slide the clamp assembly onto 
both pieces. 
5. Hand-tighten the clamp firmly onto the chamber. 
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6. Vertically rotate the assembled chamber to wet the slides and assess the mobility of the bubbles. 
Tap the assembly on a hard surface if necessary to move stationary bubbles. 
7. Put assembled slide chamber in the rotator rack in a hybridization oven set to 65 °C. Set your 
hybridization rotator to rotate at 20 rpm. 
8. Hybridize at 65 °C: • 24 hours for blood, cell and tissue samples (4x and 8x microarrays) • 40 
hours for blood, cell and tissue samples (1x and 2x microarrays) • 40 hours for FFPE samples (1x, 
2x, 4x and 8x microarray) 
 
Step 2. Wash Preparation 
Cleaning with Milli-Q Water Wash 
Rinse slide-staining dishes, slide racks and stir bars thoroughly with high-quality Milli-Q water 
before use and in between washing groups. 
a Run copious amounts of Milli-Q water through the slide-staining dishes, slide racks and stir 
bars. 
b Empty out the water collected in the dishes at least five times. c Repeat step a and step b until 
all traces of contaminating material are removed. 
Cleaning with Acetonitrile Wash  
Acetonitrile wash removes any remaining residue of Agilent Stabilization and Drying Solution from 
slide-staining dishes. 
a Add the slide rack and stir bar to the slide-staining dish, and transfer to a magnetic stir plate. 
b   Fill the slide-staining dish with 100% acetonitrile.  
c   Turn on the magnetic stir plate and adjust the speed   
d Wash for 5 minutes at room temperature.  
e Discard the acetonitrile as is appropriate for your site.  
f Repeat step a through step e.  
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g Air dry everything in the vented fume hood.  
h Continue with the Milli-Q water wash as previously instructed. 
Prewarming Oligo aCGH Wash Buffer 2 (Overnight) 
The temperature of Oligo aCGH Wash Buffer 2 must be at 37 °C for optimal performance. 
1  Add the volume of buffer required to a disposable plastic bottle and warm overnight in an 
incubator or circulating water bath set to 37 °C. 
2  Put a slide-staining dish into a 1.5 L glass dish three-fourths filled with milli-Q water and warm 
to 37 °C by storing overnight in an incubator set to 37 °C. 
Prewarming Stabilization and Drying Solution (Wash Procedure B Only) 
The Agilent Stabilization and Drying Solution contains an ozone scavenging compound dissolved 
in acetonitrile. The compound in solution is present in saturating amounts and may precipitate from 
the solution under normal storage conditions. If the solution shows visible precipitation, warming of 
the solution will be necessary to redissolve the compound. Washing slides using Stabilization and 
Drying Solution showing visible precipitation will have profound adverse affects on array 
performance. 
1 Put a clean magnetic stir bar into the Stabilization and Drying Solution bottle and recap. 
2 Partially fill a plastic bucket with hot water at approximately 40 °C to 45 °C (for example from a 
hot water tap). 
3 Put the Stabilization and Drying Solution bottle into the hot water in the plastic bucket. 
4 Put the plastic bucket on a magnetic stirrer (not a hot-plate) and stir.  
5 The hot water cools to room temperature. If the precipitate has not all 
dissolved replenish the cold water with hot water. 
6 Repeat step 5 until the solution is clear. 
7 After the precipitate is completely dissolved, allow the solution to equilibrate to room temperature 
prior to use. 
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Step 3. Microarray Washing 
Wash Procedure A (without Stabilization and Drying Solution) 
1 Completely fill slide-staining dish #1 with Oligo aCGH Wash Buffer 1 at room temperature. 
2 Put a slide rack into slide-staining dish #2.  Add a magnetic stir bar. Fill slide-staining dish #2 
with enough Oligo aCGH Wash Buffer 1 at room temperature to cover the slide rack. Put this dish 
on a magnetic stir plate. 
3 Put the prewarmed 1.5 L glass dish filled with water and containing slide-staining dish #3 on a 
magnetic stir plate with heating element. Fill the slide-staining dish #3 approximately three-fourths 
full with Oligo aCGH Wash Buffer 2 (warmed to 37 °C). Add a magnetic stir bar. Turn on the 
heating element and maintain temperature of Oligo aCGH Wash Buffer 2 at 37 °C; monitor using a 
thermometer. 
4 Remove one hybridization chamber from incubator and resume rotation of the others. Record 
whether bubbles formed during hybridization and if all bubbles are rotating freely. 
5 Prepare the hybridization chamber disassembly. a Put the hybridization chamber assembly on a 
flat surface and loosen the 
thumbscrew, turning counter-clockwise. 
b Slide off the clamp assembly and remove the chamber cover. 
c With gloved fingers, remove the array-gasket sandwich from the chamber base by lifting one 
end and then grasping in the middle of the long sides. Keep the microarray slide numeric barcode 
facing up as you quickly transfer the sandwich to slide-staining dish #1. 
d Without letting go of the slides, submerge the array-gasket sandwich into slide-staining dish 
#1 containing Oligo aCGH Wash Buffer 1. 
6 With the sandwich completely submerged in Oligo aCGH Wash Buffer 1, pry the sandwich open 
from the barcode end only. Do this by slipping one of the blunt ends of the forceps between the 
slides and then gently twist the forceps to separate the slides. Let the gasket slide drop to the bottom 
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of the staining dish. Remove the microarray slide, grasp it from the upper corners with thumb and 
forefinger, and quickly put into slide rack in the slide-staining dish #2 containing Oligo aCGH 
Wash Buffer 1 at room temperature. Minimize exposure of the slide to air. Touch only the barcode 
portion of the microarray slide or its edges! 
7 Repeat step 4 through step 6 for up to four additional slides in the group. A maximum of five 
disassembly procedures yielding five microarray slides is advised at one time in order to facilitate 
uniform washing. 
8 When all slides in the group are put into the slide rack in slide-staining dish #2, stir using setting 4 
for 5 minutes. Adjust the setting to get good but not vigorous mixing. 
9 Transfer slide rack to slide-staining dish #3 containing Oligo aCGH Wash Buffer 2 at 37 °C, and 
stir using setting 4 for 1 minute. 
10 Slowly remove the slide rack trying to minimize droplets on the slides. It should take 5 to 10 
seconds to remove the slide rack. 
11 Discard used Oligo aCGH Wash Buffer 1 and Oligo aCGH Wash Buffer 2. 
12 Repeat step 1 through step 11 for the next group of five slides using fresh Oligo aCGH Wash 
Buffer 1 and Oligo aCGH Wash Buffer 2 pre-warmed to 37 °C. 
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Wash Procedure B (with Stabilization and Drying Solution) 
 
 
Cy5 is susceptible to degradation by ozone. Use this wash procedure if the ozone level exceeds 10 
ppb in your laboratory. 
Always use fresh Oligo aCGH Wash Buffer 1 and Oligo aCGH Wash Buffer 2 for each wash group 
(up to five slides). 
The acetonitrile (dish #4) and Stabilization and Drying Solution (dish #5) below may be reused for 
washing up to 4 batches of 5 slides (total 20 slides) in one experiment. Do not pour the Stabilization 
and Drying Solution back in the bottle. 
1  Completely fill slide-staining dish #1 with Oligo aCGH Wash Buffer 1 at room temperature. 
2  Put a slide rack into slide-staining dish #2. Add a magnetic stir bar. Fill slide-staining dish #2 
with enough Oligo aCGH Wash Buffer 1 at room temperature to cover the slide rack. Put this dish 
on a magnetic stir plate. 
3  Put the prewarmed 1.5 L glass dish filled with water and containing slide-staining dish #3 on a 
magnetic stir plate with heating element. Fill the slide-staining dish #3 approximately three-fourths 
full with Oligo aCGH Wash Buffer 2 (warmed to 37 °C). Add a magnetic stir bar. Turn on the 
heating element and maintain temperature of Oligo aCGH Wash Buffer 2 at 37 °C; monitor using a 
thermometer. 
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4 In the fume hood, fill slide-staining dish #4 approximately three-fourths full with acetonitrile. 
Add a magnetic stir bar and put this dish on a magnetic stir plate. 
5 In the fume hood, fill slide-staining dish #5 approximately three-fourths full with Stabilization 
and Drying Solution. Add a magnetic stir bar and put this dish on a magnetic stir plate. 
6 Remove one hybridization chamber from incubator and resume rotation of the others. Record 
whether bubbles formed during hybridization, and if all bubbles are rotating freely.  
7 Prepare the hybridization chamber disassembly. 
a Put the hybridization chamber assembly on a flat surface and loosen the thumbscrew, turning 
counter-clockwise. 
b Slide off the clamp assembly and remove the chamber cover. 
c With gloved fingers, remove the array-gasket sandwich from the chamber base by lifting one 
end and then grasping in the middle of the long sides. Keep the microarray slide numeric barcode 
facing up as you quickly transfer the sandwich to slide-staining dish #1. 
d Without letting go of the slides, submerge the array-gasket sandwich into slide-staining dish 
#1 containing Oligo aCGH Wash Buffer 1. 
8 With the sandwich completely submerged in Oligo aCGH Wash Buffer 1, pry the sandwich open 
from the barcode end only. Do this by slipping one of the blunt ends of the forceps between the 
slides and then gently twist the forceps to separate the slides. Let the gasket slide drop to the bottom 
of the staining dish. Remove the microarray slide, grasp it from the upper corners with thumb and 
forefinger, and quickly put into slide rack in the slide-staining dish #2 containing Oligo aCGH 
Wash Buffer 1 at room temperature. Minimize exposure of the slide to air. Touch only the barcode 
portion of the microarray slide or its edges! 
9 Repeat step 6 through step 8 for up to four additional slides in the group. A maximum of five 
disassembly procedures yielding five microarray slides is advised at one time in order to facilitate 
uniform washing. 
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10 When all slides in the group are placed into the slide rack in slide-staining dish #2, stir using 
setting 4 for 5 minutes. Adjust the setting to get good but not vigorous mixing. 
11 Transfer slide rack to slide-staining dish #3 containing Oligo aCGH Wash Buffer 2 at 37 °C, and 
stir using setting 4 for 1 minute. 
12 Remove the slide rack from Oligo aCGH Wash Buffer 2 and tilt the rack slightly to minimize 
wash buffer carry-over. Quickly transfer the slide rack to slide-staining dish #4 containing 
acetonitrile, and stir using setting 4 for 10 seconds. 
13 Transfer slide rack to slide-staining dish #5 filled with Stabilization and Drying Solution, and 
stir using setting 4 for 30 seconds. 
14 Slowly remove the slide rack trying to minimize droplets on the slides. It should take 5 to 10 
seconds to remove the slide rack. 
15 Discard used Oligo aCGH Wash Buffer 1 and Oligo aCGH Wash Buffer 2. 
16 Repeat step 1 through step 15 for the next group of five slides using fresh Oligo aCGH Wash 
Buffer 1 and Oligo aCGH Wash Buffer 2 prewarmed to 37 °C. 
17 Immediately put the slides with Agilent barcode facing up in a slide holder with an ozone-barrier 
slide cover on top of the array . 
18 Scan slides immediately to minimize impact of environmental oxidants on signal intensities. If 
necessary, store slides in original slide boxes in a N2 purge box, in the dark. 
19 Dispose of acetonitrile and Stabilization and Drying Solution as flammable solvents.  
 
Step 4. Microarray Scanning using Agilent SureScan, C or B Scanner 
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Figure 8: agilent scanner  
 
Step 5. Data Extraction using Feature Extraction Software 
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5.1 Clinical results 
 
In our study we analyzed 14 samples of DNA from 13 patients affected by ONB and treated at the 
Ospedale di Circolo di Varese, University of Insubria  
Gender and age. Patients are 6 male and 7 females and aged from 33 to 80 years old. 
Presenting Symptoms. 13 patients complained of nasal obstruction either alone or associated with 
other symptoms; epistaxis in 8, mucous rhinorrhea in 6, headache in 3. One patient was 
asymptomatic and the diagnosis was incidental.  
Site of Origin. All the tumors arose in the olfactory cleft. 
Stage. According to the Kadish classification, the disease in 7 patients was classified as stage B and 
in 6 patients as stage C.  
Hyams’ Grading. Pathologic differentiation according to the Hyam’s criteria revealed 1 patient 
Hyam’s grade I, 10 patient Hyam’s grade II and 2 patients Hyam’s grade III. Grade I and II lesions 
are considered as low-grade tumors while grade III and IV lesions are considered as high-grade 
tumors.  
Treatment. 11/13 patients underwent an endoscopic resection with trasnasal craniectomy (ERTC), 
2 patients underwent a cranioendoscopic resection due to the intracranial involvement laterally to 
the virtual plane passing the lamina papyracea. 
12/13 patients underwent an adjuvant RT on the primary site of tumour, one patient refused 
postoperative radiotherapy. In 1 patient RT was administered  in association with systemic 
chemotherapy postoperatively, due to the periorbital extension and the young age. The mean dosage 
administered was 60 Gy. 
Intraoperative Margins. In 12/13 of these cases, surgical margins were free of disease, in only one 
case with massive intracranial intradural involvement, extended laterally over the orbital roof, 
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infiltration of the margins was observed. This patient underwent an andoscopic endonasal resection 
becasuse the old age and the comorbidities contraindicated the external approach (cranioendoscopic 
approach). 
Local, Regional and Distant Recurrence 
2 patients presented a local recurrence of disease; none of the patients presented distant metastasis.  
Survival. All the patients are alive: 2/13 alive with disease and 11/13 free of disease. Follow-up 
ranged from 14 to 179 months. Every patient regained his or her normal daily activities with 
excellent quality of life.  
 
5.2 Hystopatological results 
 
The olfactory neuroblastoma showed a low number of mitosis (counted in 10 fields at high 
magnification X400): on average 2 mitosis, with a variability between 0 and 6 mitoses; counts of 
MIB-1 (Ki-67) of 2000 neoplastic cells, showed a proliferative index of about 10%, with a range 
between 2% and 20%. In most cases, was not present angioinvasione and no tumour showed signs 
of neuroinvasione. In 7 patients bony structures invasion was present. Furthermore, only in 2 cases 
there were areas of necrosis. 
In poorly differentiated neuroendocrine carcinomas mitotic counts for 10 HPF, was much higher 
(with an average value of 30 and with a variability of between 20 and 60 mitosis), the proliferative 
index MIB-1 (Ki-67, counted of 2000 cells) was equal to 46% with a variability between 20% and 
80%. 
In all cases it was evident the presence of necrosis, often with the characteristic appearance to 
"map". The angioinvasione, the neuroinvasione and infiltration of bone were present only in small 
part. 
In olfactory neuroblastoma staining for synaptophysin was present in most cases, as the 
immunoreactivity for chromogranin A. It was also observed the expression of S-100 protein, and 
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not of cytokeratins. 
While neuroendocrine carcinomas, cytokeratin AE1/AE3 was expressed in all carcinomas and there 
was no immunoreactivity for S100 protein. 
5.3 a-CGH results 
 
All a-CGH results are reported in Table 11 Chromosome gains are more common than losses and 
the most frequently affected chromosomes are 20 (in 9 samples out 14), 14 (9 samples out of 14), 
19 (10 samples out of 14), 15 (8 samples out of 14), 17 (8 samples out of 14), 11,16, X (7 samples 
out of 14), 2 (6 samples out of 14), 13 (5 samples out of 14), 9 (2 samples out of 14), 21 (3 samples 
out 14), 10, 12 ( 1 sample out of 14). Only 2 samples show multiple losses of entire chromosomes. 
Frequent imbalances due to structural rearrangements are found in most chromosomes except 
3,4,6,9,13,18 e X. Only one tumor do not display any imbalaces. In patient 1, in whom we tested 
both the primitive and relapsed tumor, no loss of an entire chromosome is observed in either 
samples. Notably, we observe an increased number of partial gains in the relapse, while the partial 
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  1+ 2+ 3+ 4+ 5+ 6+ 7+ 8+ 9+ 10+ 11+ 12+ 13+ 14+ 15+ 16+ 17+ 18+ 19+ 20+ 21+ 22+ X+ Y+ 
Pz.1-P   pq     pq pq pq   pq   pq   13q12-13q31.1   q pq pq pq pq pq     pq   
PZ.1-R   p     pq pq pq       pq                           
    q12-2q35                                             
    2q36.1-2q36.3                                             
Pz.2                     pq     q q     pq p pq         
Pz.3   2p12-2q12.1     pq   pq       pq   q q q pq   pq pq pq q q pq   
Pz.  4         5p13.3-p14.3 6p21.1-p22.2 7p22.1-pter       11p15.4-pter     14q32.11-qter   16p pq 18q22.1 19p 20p13-pter 21q22.11-qter pq     
              7q11.22-22.11       11p11.12-p11.2               9q 20q         
              7q22.1       11q12.2-q14.4                           
                      11q23.1-qter                           
Pz. 5         pq pq pq       pq   13q pq pq pq pq pq pq pq   pq pq pq 
Pz. 6 1q32.1-q32.2 pq     pq pq pq       pq     pq pq pq pq pq pq pq   pq     
Pz. 7                                                 
Pz. 8         pq pq pq 8p12-p21.1 pq   q p p p p pq pq pq   pq   q     
pz.9         pq pq pq       pq     q q pq pq pq pq pq   q pq pq 
pz.10             7p21.3-pter   9p13.1-p13.3   11p15.4-pter                 pq         
              7qcen-q21.11   9q33.2-qter   11q12.1-14.1                           
              7q22.1-q22.2       11q22.3-qter                           
pz.11   pq     pq pq pq     pq pq pq q q q pq pq   pq pq   q     
pz.12   pq     pq pq pq       11pter-q22.3   pq pq   pq pq   pq pq 21q21.1-21.2 pq     
pz.13   pq     pq pq pq       pq     pq pq pq pq   pq pq 21q21.1-21.2 pq pq   
 
Table 11: amplificated regions for patient and for chromosomes showed by the a-CGH 
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 Table 12: loss regions for patients and for chromosomes showed by the a-CGH  
 
The most frequent alterations involved the amplification of chromosoma 5,7, 11 and 20, which are presented in 80% of the patients. Alterations 
occurring in at least 60% of the cases are amplification of whole chromosoma 16, 17, 19, amplification of short arm of chromosome (p) 6 and 
  1- 2- 3- 4- 5- 6- 7- 8- 9- 10- 11- 12- 13- 14- 15- 16- 17- 18- 19- 20- 21- 22- X- Y- 
1-P p31.1-p12                                             q 
  q23.1-q25.1                     q24.21                         
1-R  p31.1-p12                                               
  q23.1-q25.1                                             q 
2                                                 
3                                               q 
4 1 (complesso)   3 compl pq       pq 9 compl pq   12 compl pq   pq           q21.1-q21.3   p11.4-21.3   
5 q31.1-q32.1   3pcen-p12.3         p23.1-p23.2                                 
      3q21-q26.2                                           
6                                                 
7                                                 
8                                                 
9                                                 
10 pcenp33   pq pq       pq   pq 11p11.2-p12 p                         
  q23.1-qter                     qcen-q13.11                         
                        q14.1-q24.11                 q21.1-q22.11     pq 
11                                                 
12 p32.3-13.2                                 pter-q12.1         p21.1   
13                                                 
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amplification of long arm of chromosome (q) 14, 18 and 22. 
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Figure13: percentage of patients with DNA gain or loss for each chromosome. The Y axis shows the percentage of patients with gain or loss in chromosome. The X axis 
indicates the chromosome number.  
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Figure 16: percentage of patients with DNA gain or loss for each chromosome. The Y axis shows the percentage of patients with gain or loss in chromosome. The X axis 
indicates the chromosome number. FRESH= tumor tissue obtained during surgery 
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  1+ 2+ 3+ 4+ 5+ 6+ 7+ 8+ 9+ 10+ 11+ 12+ 13+ 14+ 15+ 16+ 17+ 18+ 19+ 20+ 21+ 22+ X+ Y+ 
Pz.1   2p12-2q12.1     pq   pq       pq   q q q pq   pq pq pq q q pq   
Pz. 2         pq pq pq 8p12-p21.1 pq   q p p p p pq pq pq   pq   q     
pz.3   pq     pq pq pq       11pter-q22.3   pq pq   pq pq   pq pq 21q21.1-21.2 pq     
pz.4   pq     pq pq pq       pq     pq pq pq pq   pq pq 21q21.1-21.2 pq pq   
  
Table 13: amplificated regions in fresh tissue samples showed by the a-CGH 
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  1- 2- 3- 4- 5- 6- 7- 8- 9- 10- 11- 12- 13- 14- 15- 16- 17- 18- 19- 20- 21- 22- X- Y- 
Pz.1                                               q 
Pz. 2                                                 
pz.3 p32.3-13.2                                 pter-q12.1         p21.1   
pz.4                                                 
 
 
Table 14: loss regions in fresh tissue samples showed by the a-CGH  
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% patients with DNA alterations 
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Figure 17: percentage of patients with DNA gain or loss for each chromosome. The Y axis shows the percentage of patients with gain or loss in chromosome. The X axis 


































P   pq     pq pq pq   pq   pq   
13q12-
13q31.1   q pq pq pq pq pq     
p
q   
PZ.1-
R   p     pq pq pq       pq                           
    q12-2q35                                             
    
2q36.1-
2q36.3                                             
Pz.2                     pq     q q     pq p pq         




p22.2 7p22.1-pter       11p15.4-pter     
14q32.11-










qter pq     
              
7q11.22-
22.11       
11p11.12-
p11.2               9q 20q         
              7q22.1       
11q12.2-
q14.4                           
                      11q23.1-qter                           







q32.2 pq     pq pq pq       pq     pq pq pq pq pq pq pq   pq     
Pz. 6                                                 





pz.8             7p21.3-pter   
9p13.1-
p13.3   11p15.4-pter                 pq         
              
7qcen-
q21.11   
9q33.2-
qter   
11q12.1-
14.1                           
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7q22.1-
q22.2       11q22.3-qter                           
pz.9   pq     pq pq pq     pq pq pq q q q pq pq   pq pq   q     
 
Table 15: amplificated regions in FFPE tissue samples showed by the a-CGH 
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  1- 2- 3- 4- 5- 6- 7- 8- 9- 10- 11- 12- 13- 14- 15- 16- 17- 18- 19- 20- 21- 22- X- Y- 
1-TP p31.1-p12                                             q 
  q23.1-q25.1                     q24.21                         
1-R  p31.1-p12                                               
  q23.1-q25.1                                             q 
2                                                 
3 1 (complesso)   3 compl pq       pq 9 compl pq   12 compl pq   pq           q21.1-q21.3   p11.4-21.3   
4 q31.1-q32.1   3pcen-p12.3         p23.1-p23.2                                 
      3q21-q26.2                                           
5                                                 
6                                                 
7                                                 
8 pcenp33   pq pq       pq   pq 11p11.2-p12 p                         
  q23.1-qter                      qcen-q13.11                         
                        q14.1-q24.11                 q21.1-q22.11     pq 
9                                                 
                         
 
Table 16: loss regions in FFPE tissue samples showed by the a-CGH 
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Biases in the results of FFPE samples versus FRESH samples 
 
Formalin-fixed, paraffin embedded (FFPE) tissue samples are a suitable source for such 
retrospective studies, but there is a valid concern about coupling of array CGH with the use of 
FFPE specimens, because of the variable deegre of DNA degradation and the oxidative and 
crosslinkage effect of formalin. 
Those crosslinks cause DNA breakage during the extraction process. Another limitation is the small 
quantity of DNA obtained from often microdissected FFPE lesions. Moreover, the passage of time 
and the storage condition of  FFPE blocks influence the quality of DNA. We used FFPE samples as 
recent as possible, but we experienced anyway an increase in the deegre of DNA fragmentation and 
the loss og high molecular weight DNA  after extraction that may be observed in the aCGH results. 
As examples in figure18 it is shown the comparison of the same chromosome 1 between two 
samples from FFPE (18A and 18B) and one fresh sample (18C). 18A and 18B are the same patient 
(no.1) where 18A is relative to the onset of the pathology and 18B is the relapse. 18C is a different 
patient (no.3) at the onset of the pathology. It well evident the moving average profile (that 
indicates the chromosome imbalances of patient and should be as much linear as possible) in case 
of FFPE samples shows a fragmented profile, while in the fresh sample it is quite linear. This is due 
to the DNA integrity and in this case, it is difficult for the ADM2 algorithm of the software to 
identify the imbalances correctly. In fact, 18A and 18B show the same moving average profile, but 
in 18A  two deep deletion profiles are evidenced by the software, while in 18B, despite the profile 
of the moving average is the same, only one aberration it is shown. 
Figure 19 (A, B and C) is the same figure 18 where also the scattered plot profile is shown. This 
profile displays a green or red spot for each probe and the localization of the spot is relative to the 
fuorescence ratio of patient versus reference DNA. A wide distribution of the scattered plots, as can 
be seen in 19A and 19B, indicates DNA damage, while a tight scattered plot, as in figure 19C, 
indicates optimal DNA condition. 
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Despite the problems of DNA damage as may be found in FFPE samples, the entire chromosome 
aneuploidy are correctly seen (Figure 20, A and B the same patient (no.1, onset and relapse) for the 
duplication of chromosome 20 and 20C for the fresh sample (no.3). As shown in fig. 18A and 18B 
the average moving in fig. 20 (A-B) shows a fragmented profile, while for the fresh sample (fig. 
20C) the profile is quite linear. In fig. 21 duplication of chromosome 5 is correctly put in evidence 
in  FFPE and FRESH samples. 
So, the problem of FFPE samples is only relative to little regions of chromosome imbalances, while 
for entire chromosome aneuploidy (very frequent in ONB) the problem is less relevant. 
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Fig.18     A                                                      B                                                           C 
 
   
 
Fig.19   A                                                        B                                                           C  
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Olfactory neuroblastoma (ONB) arises from the neural-epithelial olfactory mucosa. The mainstay 
treatment of ONB generally comprises radical surgical resection6. In our experience, surgical 
excision should include the dura of the ASB together with the ipsilateral olfactory bulb in every 
case, not only to obtain a free-margins resection of the disease but also for staging purposes6. The 
removal of both olfactory bulbs is performed only for bilaterally extended cancers. Postoperative 
irradiation has been shown to reduce local recurrence rates and improve survival, so it is 
recommended in all cases, irrespective of extent of disease at diagnosis1,47. Radiation treatment is 
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typically delivered using IMRT, which provides optimal sparing of radiation dose to sensitive 
normal structures, such as the optic nerve or brain. The recent introduction of intensity-modulated 
proton beam radiation therapy (IMPBRT) deserves particular mention, showing promising results 
for the management of ONB both as exclusive primary therapy and in the postoperative setting48. 
Cervical lymph node metastases are infrequent at presentation for patients diagnosed with ONB, 
with reported rates between 5% and 12%. However, given the high reported rates of late regional 
failures and limited morbidity-associated IMRT, elective neck radiation may warrant consideration 
in patients with intracranial disease at presentation (Kadish C)1. Particular attention should be paid 
to Hyams grading, which accurately characterizes tumor biology and represents an independent 
predictor of locoregionally recurrence of disease and overall survival (OS)47. For this reason, it is a 
valuable asset to consider when contemplating adjuvant or neoadjuvant therapies. In detail, poorly 
differentiated ONB, namely Hyams grade IV lesions, presenting in locally advanced stages (T3–
T4), could benefit from different regimens of induction chemotherapy (etoposide/cisplatin49 or 
cyclophosphamide/vincristine50,51) to improve both disease control and survival rates; however, the 
existing data do not provide any definitive indication in this field. 
 
 
A-CGH is a relatively new technology designed to allow high throughput screening of 
chromosomal gains and losses in diseases, particularly cancer. 
Cytogenetic data on ONB from literature are scarce and rather sparce; the aim of our study is to 
identify DNA copy number changes  in ONB by aCGH.  
We decided to compare our results with those of Guled et al. (2008) 7, who reported a-CGH results 
obtained on 13 patients, and reviewed all previous reports in the literature. Previous data were based 
on combined results of conventional chromosome analysis, locus-specific fluorescence in situ 
hybridization (FISH), multicolor FISH, CGH, and single nucleotide polymorphism (SNP) array 
techniques. A total of 31 patients were reported in the literature for whom some kind of cytogenetic 
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data were available. In their patient cohort, Guled et al. indicated several regions that were gained in 
a significant proportion of cases: 7q11.2, 20q13, 5q34-35, 6p12.3, 10p12.31, and 12q23.1-24.31. 
They observed recurrent losses in 2q31-37, 5q, 6p, 6q, 18q, 15q11.2-24.1, 15q13.1, 19q12-13, 
22q11.1-11.21, 22q11.23, and 22q12.1. Most segmental gains and losses found in our patients were 
different from the imbalances claimed as recurrent by Guled et al., and the only corresponding data 
concerned the gain of band 20q13 and the loss of segments of chromosomes 15 and 22 (Table 11-
12). Guled et al., however, only reviewed previous data that were useful for a comparison with their 
own results. Thus, we reanalyzed all available data in the literature7,40,41,42,43,52 and compared them 
with our results. We remark, however, that our results and those of Guled et al (2008) identify more 
precisely the chromosome segments gained and lost in comparison with previous studies. For 
instance, gains and losses of chromosomes 15 and 20 found in our cases concerned small segments 
that were similar, but not identical to those previously reported as frequent; in another case, the 
region lost on chromosome 22 was adjacent, but different from the one already identified. Weiss et 
al.52 applied Next Generation Sequencing (NGS) to one patient with ONB, and they precisely 
identified regions gained or lost. A comparison with our data showed the following similarities: 
they showed the gain of the short arms of chromosome 8, and we found the gain of the region 
8p21.1-21.2 in one patient. They noted the gain of two chromosome 16 regions, 16q22.1 and 
16q24.3: similarly, we observed the gain of 16q21-22.2 in one patient and of the entire long arms of 
chromosome 16 in another subject (Table 11). They reported the loss of 19p12, while we found the 
loss of 19p11-12 in one patient; they indicated the loss of 21q1, and we found the loss of 21q11.1-
21.3 (Table 12). These were the only similar anomalies observed, although the regions involved 
were not identical. Thus, as far as segmental chromosome imbalances are concerned, it was not 
possible to make conclusions on real recurrent regions gained or lost, although a high level of 
chromosome instability was confirmed.  
In our cohort, eleven out of 13 samples revealed gains of several entire chromosomes; and no gains 
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or losses in one patient (Table 11-12). The comparison with literature data is inconsistent, except 
for the gain of chromosome 19, present in 10/14 of our samples and in 3/3 patients reported by 
Riazimand et al.41. Otherwise, few gains and losses of entire chromosomes have been reported. 
Of interest, in patient no.1 a comparison of the primary and relapsed tumor showed a clonal 
evolution. The number of trisomies was reduced, while several segmental gains were added, and 
segmental losses were identical except for 10q25.1 (Table 11-12). 
Archived FFPE specimens allow for the retrospective study of a large number of cases but are 
limited by potentially suboptimal DNA quality. 
PCR amplicon size and storage period were key factors influencing the success rate of DNA 
extraction from FFPE samples. Another major factor affecting the DNA quality is the presence of 
necrosis in tissue specimens. It is likely that the adverse effect of necrosis is due to the DNA 
degradation of necrotic cells. However, such DNA degradation contributed by necrosis could not be 
revealed by PCR-based assessment of DNA integrity, as it would be masked by the relatively intact 
DNA from ‘viable’ cells53,54,55,56. However, necrosis is easily identified by histological review and 
its adeverse effect on aCGH can be eliminated by microsdissection57. In line with loss of 
eterozygosity analysis, sensitivity of aCGH in detection of DNA copy number changes heavily 
depends on the proportion of tumor cells in a tissue specimen. Together with the adverse effect of 
necrosis, this emphasises the importance of routine histological review of tissue specimens selected 
for aCGH58. 
In the fresh-frozen samples, the DNA extraction success rate was 100% using either a commercial 
kit (QIAamp DNA Micro) or a laboratory based method regardless of PCR amplicon length or 
tissue storage time59. 
Our results show how the problem of quality of aCGH of FFPE samples is principally relative to the 
identification of little regions of chromosome imbalances, while for entire chromosome aneuploidy, 
that are very frequent in olfactory neuroblastomas, the problem is less relevant. Undoubtedly we 
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can conclude that the optimal method for DNA extraction and for aCGH analysis is the use of fresh-
frozen samples. 
Our efforts to identify important chromosome imbalances in ONB pathogenesis and disease course 
are largely inconclusive: no specific segmental chromosome anomalies were consistently present in 
a significant proportion of the tumors. We were not able to confirm most of the conclusions. The 
exceptions were frequent gain of chromosome 19, gain of some regions of the long arm of 20, while 
some regions of the long arm of 22 were often lost. Our data do not indicate a correlation between 
imbalances and Kadish stage or Hyams’ grade. 
However these preliminary results, although obtained in only 13 patients, demonstrated that the a-
CGH is a tool of fundamental importance in the study of cytogenetic abnormalities in solid tumors. 
Therefore the results obtained in our study, could contribute in the future to better define the 
cytogenetic profile of ONB , to identify possible correlations with clinical and pathological features 
and also to find targeted therapeutic protocols. 
A-CGH will require further analysis based on larger series to determine the role of the regions 
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